$1.12
6.29% today
Nasdaq, Apr 04, 09:39 pm CET
ISIN
US00972G1085
Symbol
AKTX
Sector
Industry

Akari Therapeutics Plc Sponsored ADR Stock price

$1.19
+0.25 27.00% 1M
-1.81 60.33% 6M
-0.03 2.46% YTD
-0.36 23.23% 1Y
-22.51 94.98% 3Y
-24.61 95.39% 5Y
-146.81 99.20% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.09 8.18%
ISIN
US00972G1085
Symbol
AKTX
Sector
Industry

Key metrics

Market capitalization $14.45m
Enterprise Value $13.40m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Cash position $2.25m
Short interest 0.23%

Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

Buy
100%

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 1.71 1.71
-
-
- Research and Development Expense 0.14 0.14
-
-
-1.85 -1.85
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1.85 -1.85
-
-
Net Profit -2.90 -2.90
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
15 days ago
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B
Neutral
GlobeNewsWire
about one month ago
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross...
Neutral
GlobeNewsWire
about one month ago
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Dr. Samir ...
More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Samir Patel
Founded 2004
Website www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today